Drepmel—A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment

Although substantial progress has been made in treating patients with advanced melanoma with targeted and immuno-therapies, de novo and acquired resistance is commonplace. After treatment failure, therapeutic options are very limited and novel strategies are urgently needed. Combination therapies ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Zachary J., Teer, Jamie K., Li, Jiannong, Chen, Zhihua, Welsh, Eric A., Zhang, Yonghong, Ayoubi, Noura, Eroglu, Zeynep, Tan, Aik Choon, Smalley, Keiran S. M., Chen, Yian Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497118/
https://www.ncbi.nlm.nih.gov/pubmed/36139469
http://dx.doi.org/10.3390/cells11182894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497118/
https://www.ncbi.nlm.nih.gov/pubmed/36139469
http://dx.doi.org/10.3390/cells11182894

Ejemplares similares